Naunyn-Schmiedeberg's archives of pharmacology · 2016
Rosemary (Rosmarinus officinalis) as a potential therapeutic plant in metabolic syndrome: a review.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hassani Faezeh Vahdati, Shirani Kobra, Hosseinzadeh Hossein
Аннотация
Metabolic syndrome is defined by a constellation of complex coexisting cardiometabolic risk factors such as hyperglycemia, dyslipidemia, inflammation, abdominal obesity, coagulopathies, and hypertension that raise the risk of diabetes mellitus and cardiovascular disease. Recently, there has been an increasing interest in the use of herbs and natural compounds in prevention and treatment of diseases and a large number of published articles have focused on this issue. Rosmarinus officinalis L. or rosemary (Lamiaceae) is a rich source of phenolic phytochemicals having significant anti-oxidant, anti-inflammatory, hypoglycemic, hypolipidemic, hypotensive, anti-atherosclerotic, anti-thrombotic, hepatoprotective, and hypocholesterolemic effects. The purpose of this review is to highlight the interesting pharmacological effects of rosemary, and its active compounds, and the related mechanisms in the management of metabolic syndrome that are documented in in vitro and in vivo studies.
Предметные рубрики MeSH
AnimalsAnti-Inflammatory AgentsAnti-Obesity AgentsAntioxidantsBiomarkersBlood GlucoseCardiovascular AgentsCardiovascular DiseasesGluconeogenesisHumansHypoglycemic AgentsHypolipidemic AgentsInflammation MediatorsLipidsMetabolic SyndromeOxidative StressPhytotherapyPlant ExtractsPlants, MedicinalRisk FactorsRosmarinusWeight Gain